Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors including genes, factors such as stress and brain chemistry that could lead to depression. According to WHO almost 350 million people worldwide were affected with depression in 2016. Antidepressants help maintain balance of various hormones and chemicals in the brain, which helps in the treatment of depression. The global anti-depressant drugs market was valued at $13,755 million in 2016, and is estimated to reach $15,983 million by 2023, registering a CAGR of 2.1% from 2017 to 2023.

Key Benefits

This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
The global market is comprehensively analyzed with respect to type, method, technology, end user, and region.
In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Anti-depressant Drugs Market Key Segments:
By Depression Disorder

Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others

By Product

Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-norepinephrine reuptake Inhibitors
Monoamine oxidase inhibitors
Serotonin antagonist and reuptake inhibitors
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA